Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Cited by 22 Publications

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2082

PubMed: 27182663 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3197-3203

PubMed: 29559562 ( click the link to review the publication )

Clin Cancer Res., 2017, 23(15):4364-4375

PubMed: 28246274 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2015, 10.1021/am5090226

PubMed: 25811662 ( click the link to review the publication )

Biomacromolecules, 2014, 15(11):4187-94

PubMed: 25251833 ( click the link to review the publication )

Int J Radiat Oncol, 2015, 91(4):807-16

PubMed: 25752395 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.05.005

PubMed: ( click the link to review the publication )

Am J Cancer Res, 2017, 7(4):903-912

PubMed: 28469962 ( click the link to review the publication )

Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313 ( click the link to review the publication )
Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313 ( click the link to review the publication )

Surgery, 2014, 10.1016/j.surg.2014.10.007

PubMed: ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2012, 71(13):4707-19

PubMed: 21555371 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

RSC Adv, 2011, 1:884-892

PubMed: ( click the link to review the publication )

Bioorg Med Chem, 2012, 21(4):922-31

PubMed: 23306053 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155052

PubMed: 27148873 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 453(3):392-7

PubMed: 25268318 ( click the link to review the publication )

J Nanopart Res, 2014, 16:2340

PubMed: ( click the link to review the publication )

6 Customer Reviews

(F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

Effect of tivantinib on the mitotic index was compared with the antimitotic drugs paclitaxel and vinblastine after overnight treatment of the HLE cell line with two different concentrations of each drug.

Clin Cancer Res, 2017, 23(15):4364-4375. Paclitaxel purchased from Selleck.
Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.
Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Targets

Microtubule (human endothelial cells) ^[1]

0.1 pM

In vitro

Paclitaxel inhibits non-endothelial type human cells at 10⁴ - to 10⁵ -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. ^[1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. ^[2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
TE-15	NV7xOY97T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3TbIVKSzVyPUCuNFAxOjh5IN88US=>	NGjxdYlUSU6JRWK=
LC-2-ad	MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLZeotKSzVyPUCuNFAxOzF5IN88US=>	NYPpWlZYW0GQR1XS
RL95-2	MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoX2TWM2OD1yLkCwNFY3QCEQvF2=	NXzlXlM4W0GQR1XS
MZ1-PC	MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwMECwO\|I6KM7:TR?=	MVrTRW5ITVJ?
TE-8	MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPWR21pUUN3ME2wMlAxOTF5IN88US=>	MljHV2FPT0WU
SW954	M4PkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIm3VGZKSzVyPUCuNFAyOTlizszN	NXLhbmNCW0GQR1XS
TE-11	Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;ZZWlEPTB;MD6wNFEzOyEQvF2=	MX7TRW5ITVJ?
PSN1	MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4KwT2lEPTB;MD6wNFE{KM7:TR?=	MnfHV2FPT0WU
MOLT-4	NV3PN2JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XHPWlEPTB;MD6wNFE1QSEQvF2=	MWjTRW5ITVJ?
697	NIXIVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYT6PVgzUUN3ME2wMlAxOTVizszN	M3T0SHNCVkeHUh?=
ETK-1	NHnLXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFq0eXVKSzVyPUCuNFAyPTJizszN	M4mxU3NCVkeHUh?=
TE-10	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3aTWM2OD1yLkCwNVU1KM7:TR?=	MnzsV2FPT0WU
HUTU-80	NYf3[HZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3YTWM2OD1yLkCwNVY5KM7:TR?=	MormV2FPT0WU
NTERA-S-cl-D1	NEnxVGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XZXmlEPTB;MD6wNFIxQSEQvF2=	M1HiZnNCVkeHUh?=
MFH-ino	NVfBNIV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF[4W2NKSzVyPUCuNFAzPjhizszN	MUjTRW5ITVJ?
IA-LM	M1jVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NID4bmdKSzVyPUCuNFAzQCEQvF2=	MlTYV2FPT0WU
MC116	NHe4N3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{izOWlEPTB;MD6wNFI5QSEQvF2=	MYfTRW5ITVJ?
RKO	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfzbYtKUUN3ME2wMlAxOjl6IN88US=>	NV\5RVZzW0GQR1XS
MRK-nu-1	MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMECyPVkh\|ryP	Mn72V2FPT0WU
VA-ES-BJ	NVLxWpMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMECzJO69VQ>?	M4jacHNCVkeHUh?=
KALS-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLNTWM2OD1yLkCwN\|A5KM7:TR?=	Mn[5V2FPT0WU
BB30-HNC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzqVJA2UUN3ME2wMlAxOzF2IN88US=>	MmjQV2FPT0WU
ACN	NHG0OmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwMECzNVYh\|ryP	NWXTbo93W0GQR1XS
TE-9	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTBwMECzNlYh\|ryP	NYHBeY1JW0GQR1XS
SIG-M5	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMECzNlch\|ryP	MWTTRW5ITVJ?
no-10	NYq5VXV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjKVZpuUUN3ME2wMlAxOzZ{IN88US=>	NUnh[G1bW0GQR1XS
EW-1	NWHDVox2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwMECzO\|Eh\|ryP	NEG2O5RUSU6JRWK=
SK-LMS-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7SWJE4UUN3ME2wMlAxPDBzIN88US=>	M{LuXnNCVkeHUh?=
GT3TKB	MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDRcXBKSzVyPUCuNFA1OzRizszN	NGnqUXRUSU6JRWK=
ES4	NIDme2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTtTWM2OD1yLkCwOFQ6KM7:TR?=	NHfZXHNUSU6JRWK=
IMR-5	M1fVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW[welJXUUN3ME2wMlAxPDVizszN	NW\2[GtlW0GQR1XS
NCI-H1648	Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoT3TWM2OD1yLkCwOFY6KM7:TR?=	M4q5W3NCVkeHUh?=
MV-4-11	NIT4VmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3z0bWlEPTB;MD6wNFQ4PSEQvF2=	MYXTRW5ITVJ?
SK-UT-1	MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTtTWM2OD1yLkCwOFgh\|ryP	NVvpb5JwW0GQR1XS
NB13	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\CTWM2OD1yLkCwOFkyKM7:TR?=	NWe0RWc6W0GQR1XS
DJM-1	M3;TdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvJOWlKSzVyPUCuNFA2OyEQvF2=	NU\xT2VmW0GQR1XS
ES8	NVzPb\|g2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonITWM2OD1yLkCwOVM5KM7:TR?=	MYjTRW5ITVJ?
TE-6	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rWXWlEPTB;MD6wNFU4KM7:TR?=	Ml3tV2FPT0WU
KS-1	NGPKNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTBwMEC1PFIh\|ryP	MlXGV2FPT0WU
TE-1	MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwMEC2NFYh\|ryP	MXHTRW5ITVJ?
ATN-1	NF[4SFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2G0WmlEPTB;MD6wNFYxQSEQvF2=	M4jI[3NCVkeHUh?=
A4-Fuk	NH\yU\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7WbFRlUUN3ME2wMlAxPjFzIN88US=>	M2rzSHNCVkeHUh?=
ALL-PO	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjyemRKSzVyPUCuNFA3OyEQvF2=	NXfReXY5W0GQR1XS
BE-13	M1PwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV2ySY1FUUN3ME2wMlAxPjN4IN88US=>	MkXMV2FPT0WU
KM12	NELRW\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUO1cIxZUUN3ME2wMlAxPjN5IN88US=>	MoC3V2FPT0WU
NOS-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nlWWlEPTB;MD6wNFY2KM7:TR?=	MVPTRW5ITVJ?
SW962	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;UT2lEPTB;MD6wNFY3OiEQvF2=	NFL6bJlUSU6JRWK=
OCUB-M	NFTmSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rO[2lEPTB;MD6wNFY3OiEQvF2=	M2rVXXNCVkeHUh?=
NCI-H510A	NFLjPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\Rb4hHUUN3ME2wMlAxPjZ3IN88US=>	M3v0T3NCVkeHUh?=
EW-16	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jHfGlEPTB;MD6wNFY6PCEQvF2=	M4TQUHNCVkeHUh?=
KGN	MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFP6RYdKSzVyPUCuNFA4OTJizszN	MUnTRW5ITVJ?
LS-411N	NFLDe\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwMEC3NVch\|ryP	Mkf6V2FPT0WU
Becker	NWHOO2I{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwMEC3NkDPxE1?	Mm\0V2FPT0WU
HC-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn6zTWM2OD1yLkCwO\|IyKM7:TR?=	NGXrbplUSU6JRWK=
CESS	M1LrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLIVodrUUN3ME2wMlAxPzN5IN88US=>	MYLTRW5ITVJ?
KURAMOCHI	NUT1OnYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PzPGlEPTB;MD6wNFc1QCEQvF2=	NVG4eGNPW0GQR1XS
TGBC24TKB	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLhTWM2OD1yLkCwO\|UzKM7:TR?=	NG\pSHJUSU6JRWK=
SW982	Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHn1WHhKSzVyPUCuNFA4PjZizszN	NF\MW3JUSU6JRWK=
HCE-4	M1i2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLkdFlKSzVyPUCuNFA4PjdizszN	M3\vbHNCVkeHUh?=
LOUCY	NXW2bVF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojsTWM2OD1yLkCwO\|c2KM7:TR?=	M4HH[HNCVkeHUh?=
8-MG-BA	NY\4W2RiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYP6fIFmUUN3ME2wMlAxPzl4IN88US=>	NG\MNGhUSU6JRWK=
HT-144	NXHHOFJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljoTWM2OD1yLkCwPEDPxE1?	MUjTRW5ITVJ?
LXF-289	NXzGVYlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrMTWM2OD1yLkCwPFE5KM7:TR?=	M4qzR3NCVkeHUh?=
RS4-11	NXy5d5c{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrsb3BKSzVyPUCuNFA5OzZizszN	MnjtV2FPT0WU
DEL	NXjBOJBFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYmxRWpSUUN3ME2wMlAxQDR3IN88US=>	NXXwdJhYW0GQR1XS
OCI-AML2	NHq5eZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHtN49nUUN3ME2wMlAxQDV{IN88US=>	NVHLPVZyW0GQR1XS
CCRF-CEM	NUPvNlFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTBwMEC4O\|Eh\|ryP	NXj1SIY3W0GQR1XS
A388	NX3tU\|NwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jxcGlEPTB;MD6wNFg4PCEQvF2=	NFT1UVhUSU6JRWK=
KNS-42	M2C5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEmy[HpKSzVyPUCuNFA5QTFizszN	M{jiRXNCVkeHUh?=
OVCAR-4	NXri[XZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7lTVVKSzVyPUCuNFA6ODRizszN	NWGyc49LW0GQR1XS
NCI-H1355	NF3ke2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\2eGlEPTB;MD6wNFkyPCEQvF2=	NH7NNG5USU6JRWK=
BL-70	MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPwXplYUUN3ME2wMlAxQTNizszN	NXP0TJJjW0GQR1XS
BL-41	NFTHRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlO4TWM2OD1yLkCwPVM1KM7:TR?=	NYLqVGxHW0GQR1XS
A101D	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfPTWM2OD1yLkCwPVYh\|ryP	MkfxV2FPT0WU
HL-60	M3Ppemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{C5W2lEPTB;MD6wNFk3PiEQvF2=	MX;TRW5ITVJ?
COR-L279	NYDoSYp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTBwMEC5PVkh\|ryP	MofkV2FPT0WU
NCI-SNU-16	M1fzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkThTWM2OD1yLkCxNFA5KM7:TR?=	MnO2V2FPT0WU
Calu-6	M1;sTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTH[JBWUUN3ME2wMlAyODF{IN88US=>	NWCxWod1W0GQR1XS
SR	NWn1b5FXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TxZ2lEPTB;MD6wNVAzPiEQvF2=	M4r0SXNCVkeHUh?=
QIMR-WIL	M{LhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwMEGwN\|Mh\|ryP	MXXTRW5ITVJ?
LB647-SCLC	NEDV[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TncGlEPTB;MD6wNVA2OSEQvF2=	MmHWV2FPT0WU
RPMI-8226	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXCbWRmUUN3ME2wMlAyOTB{IN88US=>	Mn\sV2FPT0WU
SK-PN-DW	M3rxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwMEGxNVIh\|ryP	MVjTRW5ITVJ?
SF268	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwMEGxOVEh\|ryP	NYHwU5pZW0GQR1XS
HD-MY-Z	NIrYdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXLPHFmUUN3ME2wMlAyOTZ\|IN88US=>	MX7TRW5ITVJ?
DOHH-2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DZW2lEPTB;MD6wNVIxOyEQvF2=	M4rheHNCVkeHUh?=
SCC-3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LZR2lEPTB;MD6wNVIxPCEQvF2=	NF3LNHFUSU6JRWK=
ST486	Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLZTWM2OD1yLkCxNlA1KM7:TR?=	NVu4d5d[W0GQR1XS
NALM-6	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIT0fWZKSzVyPUCuNFEzOTRizszN	M1zUeXNCVkeHUh?=
NCI-H1436	MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFH3S2dKSzVyPUCuNFEzOzFizszN	M1nEO3NCVkeHUh?=
KE-37	M4f6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYK0SZlYUUN3ME2wMlAyOjN2IN88US=>	NYWxR5IxW0GQR1XS
RPMI-8402	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rMVmlEPTB;MD6wNVI2PiEQvF2=	MmGwV2FPT0WU
RXF393	MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfPNZI3UUN3ME2wMlAyOjV5IN88US=>	MofCV2FPT0WU
KARPAS-45	M4G1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jlfWlEPTB;MD6wNVI4KM7:TR?=	NWTBWVdvW0GQR1XS
HOP-62	NI\PRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwMEGyO\|Yh\|ryP	MnTpV2FPT0WU
ES1	MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;YS5R4UUN3ME2wMlAyOjh6IN88US=>	NETEdo1USU6JRWK=
L-363	Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2L4VmlEPTB;MD6wNVM2OSEQvF2=	NIHCRWpUSU6JRWK=
GI-1	NYLiZlFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjTTWM2OD1yLkCxN\|c{KM7:TR?=	MYTTRW5ITVJ?
CTV-1	NWP0U25kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMEG0O\|gh\|ryP	MWrTRW5ITVJ?
TE-5	NEPBZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rkc2lEPTB;MD6wNVQ6PiEQvF2=	NEnNbIVUSU6JRWK=
SNU-C2B	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHPTWM2OD1yLkCxOFk3KM7:TR?=	NUC3[VQ3W0GQR1XS
K-562	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorZTWM2OD1yLkCxOVE3KM7:TR?=	NWPFdFBLW0GQR1XS
SNB75	NGPIPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEn0TmFKSzVyPUCuNFE2PCEQvF2=	NH20T3FUSU6JRWK=
MOLT-13	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTBwMEG2N\|ch\|ryP	NWG5dVhSW0GQR1XS
LS-123	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3[4VGlEPTB;MD6wNVY3PCEQvF2=	NVLmSZpuW0GQR1XS
NCI-SNU-5	M2TjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDFfFA5UUN3ME2wMlAyPzBzIN88US=>	M4n2V3NCVkeHUh?=
Daudi	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwMEG3NFgh\|ryP	MVfTRW5ITVJ?
A253	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fh[GlEPTB;MD6wNVc{QCEQvF2=	M2XWTnNCVkeHUh?=
TGBC1TKB	NIjsXlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHaeGxKSzVyPUCuNFE4PTJizszN	NXvEcYtxW0GQR1XS
SJSA-1	Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWC2Z4o{UUN3ME2wMlAyPzZ5IN88US=>	MojqV2FPT0WU
NCCIT	MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwMEG3Olkh\|ryP	MVHTRW5ITVJ?
NCI-H69	NF;YcIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3ydYhKSzVyPUCuNFE4PzhizszN	MUPTRW5ITVJ?
SH-4	NILEdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMEG4PVUh\|ryP	Ml30V2FPT0WU
HCC1187	M3fybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLy[opFUUN3ME2wMlAyQTJ2IN88US=>	MoD0V2FPT0WU
HCC1599	MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMEKwNkDPxE1?	NEDEZWFUSU6JRWK=
ONS-76	MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rzOGlEPTB;MD6wNlA{PiEQvF2=	NU[weVJSW0GQR1XS
KU812	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXiWotlUUN3ME2wMlAzODN7IN88US=>	MWDTRW5ITVJ?
ML-2	NFXKboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjGTWM2OD1yLkCyNFQ4KM7:TR?=	Mo\IV2FPT0WU
HCE-T	NX6we4pTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrmRW9EUUN3ME2wMlAzODl{IN88US=>	M{nDbHNCVkeHUh?=
NCI-H446	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwMEKxNVIh\|ryP	MonLV2FPT0WU
RPMI-6666	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\sUWQ6UUN3ME2wMlAzOTR7IN88US=>	MVfTRW5ITVJ?
MOLT-16	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PZbmlEPTB;MD6wNlE2OyEQvF2=	MVXTRW5ITVJ?
JiyoyeP-2003	NIXOSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDNZ5NKSzVyPUCuNFIyPzZizszN	MnXhV2FPT0WU
MHH-PREB-1	NYLScWVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPtRpBkUUN3ME2wMlAzOTlzIN88US=>	Mn\EV2FPT0WU
MC-CAR	M2DXWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTZTWM2OD1yLkCyN\|I3KM7:TR?=	Mn3aV2FPT0WU
BC-3	M{nPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDvfoQzUUN3ME2wMlAzOzR2IN88US=>	NYjpVlRXW0GQR1XS
KINGS-1	MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXvTWM2OD1yLkCyN\|U2KM7:TR?=	M4PtZXNCVkeHUh?=
PF-382	Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTJPFFkUUN3ME2wMlAzOzd6IN88US=>	MmLyV2FPT0WU
J-RT3-T3-5	NVPrNFNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMEKzPFMh\|ryP	MoHFV2FPT0WU
SF539	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\ETWM2OD1yLkCyOFAyKM7:TR?=	MW\TRW5ITVJ?
LB831-BLC	M3T1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmC2TWM2OD1yLkCyOFg2KM7:TR?=	NYG3PHpOW0GQR1XS
DMS-114	NI\ne3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fl[GlEPTB;MD6wNlUxOiEQvF2=	NGDhXmRUSU6JRWK=
LB1047-RCC	M1fqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHG1SWJKSzVyPUCuNFI2OSEQvF2=	M{Xsb3NCVkeHUh?=
LB771-HNC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHYWGpKSzVyPUCuNFI2OzRizszN	NUm1fHk6W0GQR1XS
BB65-RCC	M3qyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTBwMEK1N\|Qh\|ryP	MYXTRW5ITVJ?
BV-173	NGT1[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIqyb2pKSzVyPUCuNFI2PTRizszN	MYPTRW5ITVJ?
ARH-77	MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfMd2lKSzVyPUCuNFI3ODFizszN	Mln3V2FPT0WU
IST-MEL1	NHH2[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;xTWM2OD1yLkCyOlI{KM7:TR?=	NH7yTIFUSU6JRWK=
NB1	NWfIcYRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwMEK2PFch\|ryP	MXvTRW5ITVJ?
EoL-1-cell	NIjLTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjSbWV3UUN3ME2wMlAzPjh6IN88US=>	MUTTRW5ITVJ?
KY821	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPPeZdKSzVyPUCuNFI3QTdizszN	MVjTRW5ITVJ?
CMK	NF7wTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7SNm9KSzVyPUCuNFI4OzRizszN	NIT6TWxUSU6JRWK=
NCI-H2126	MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTBwMEK3Olgh\|ryP	MXPTRW5ITVJ?
NCI-H526	NWn2b2YzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonRTWM2OD1yLkCyPFkyKM7:TR?=	NEn3clhUSU6JRWK=
COLO-684	NULodYgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPwWnRZUUN3ME2wMlAzQTB6IN88US=>	MnTiV2FPT0WU
NCI-H747	M3HjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHTTWM2OD1yLkCyPVM{KM7:TR?=	MmHDV2FPT0WU
JAR	MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfYXGFKSzVyPUCuNFI6PDZizszN	NFW0RldUSU6JRWK=
MEG-01	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3flSGlEPTB;MD6wNlk4QCEQvF2=	M4nYb3NCVkeHUh?=
MONO-MAC-6	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMEOwNlMh\|ryP	M3nVXHNCVkeHUh?=
IST-SL1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4e2bWlEPTB;MD6wN\|A1OiEQvF2=	MYLTRW5ITVJ?
CPC-N	MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMEOwO\|kh\|ryP	M{fnNHNCVkeHUh?=
NCI-H1963	NVSzXldJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2f5XGlEPTB;MD6wN\|E{OSEQvF2=	NIPnd41USU6JRWK=
K052	M1raXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1z2W2lEPTB;MD6wN\|I1PyEQvF2=	NHHTe5NUSU6JRWK=
KM-H2	M4f2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHe2[FlKSzVyPUCuNFM{ODdizszN	NIjGTYdUSU6JRWK=
TE-12	M1Li[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPxTWM2OD1yLkCzN\|A6KM7:TR?=	NV3XWmV7W0GQR1XS
TK10	NUHsRYwxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFj0eppKSzVyPUCuNFM{PTZizszN	NGnmTVVUSU6JRWK=
NMC-G1	M3XkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHQTWM2OD1yLkCzOFUzKM7:TR?=	NFj6RZpUSU6JRWK=
no-11	MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TOdmlEPTB;MD6wN\|Q4QCEQvF2=	NVLQRXpxW0GQR1XS
NCI-H524	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3OwdGlEPTB;MD6wN\|UzQSEQvF2=	NGToSVRUSU6JRWK=
MHH-CALL-2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUD1eFNnUUN3ME2wMlA{PTZ{IN88US=>	Mn7TV2FPT0WU
GB-1	M2[4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1Wyd2lEPTB;MD6wN\|Yh\|ryP	NGrOcGZUSU6JRWK=
OPM-2	MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoO1TWM2OD1yLkCzOlc{KM7:TR?=	M3\Le3NCVkeHUh?=
RH-1	M123b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\YS3dJUUN3ME2wMlA{QDF7IN88US=>	NGLLSHFUSU6JRWK=
NCI-H64	Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoW2TWM2OD1yLkCzPFU4KM7:TR?=	NEHFN49USU6JRWK=
EVSA-T	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3JNFJKSzVyPUCuNFM6OjNizszN	NFrzOoFUSU6JRWK=
KARPAS-299	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjSSFJlUUN3ME2wMlA{QThizszN	Mn:3V2FPT0WU
MZ7-mel	NVzFeVVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETwVG9KSzVyPUCuNFQxPCEQvF2=	MWTTRW5ITVJ?
LB373-MEL-D	MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1X2bmlEPTB;MD6wOFExPSEQvF2=	NH3G[npUSU6JRWK=
HEL	NVTTWVg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLhbXJKSzVyPUCuNFQyPCEQvF2=	MlTVV2FPT0WU
SW872	NU[5cmlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHFc\|hiUUN3ME2wMlA1OjFizszN	NUHHWJJFW0GQR1XS
DU-4475	NXr1V\|k5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwMESyOFQh\|ryP	NIfyNlJUSU6JRWK=
IST-SL2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nscGlEPTB;MD6wOFI4PSEQvF2=	M3viRnNCVkeHUh?=
NCI-H82	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjETWM2OD1yLkC0N\|A4KM7:TR?=	MlvoV2FPT0WU
LC4-1	M1[1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMESzOVEh\|ryP	NESwTYlUSU6JRWK=
HDLM-2	MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1THeGlEPTB;MD6wOFM6OiEQvF2=	Mn24V2FPT0WU
MMAC-SF	Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7Pemk5UUN3ME2wMlA1PTN2IN88US=>	NFu1[lVUSU6JRWK=
L-540	NYXmOmlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwMES2N\|kh\|ryP	M{DxN3NCVkeHUh?=
MZ2-MEL	MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LPfWlEPTB;MD6wOFc1OiEQvF2=	Mlv3V2FPT0WU
LU-134-A	M2jiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUOweYpkUUN3ME2wMlA1Pzd\|IN88US=>	MYrTRW5ITVJ?
UACC-257	NHHVUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnweHJKSzVyPUCuNFQ5PDlizszN	MlfsV2FPT0WU
NCI-H1581	M2DPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HzNmlEPTB;MD6wOFk2OyEQvF2=	MmLJV2FPT0WU
NB17	NFzWb2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMES5O\|kh\|ryP	MnP6V2FPT0WU
SBC-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPJNoZKSzVyPUCuNFUxPDJizszN	MXPTRW5ITVJ?
TALL-1	M2nFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLJfpc2UUN3ME2wMlA2ODR3IN88US=>	NHHsNI9USU6JRWK=
NCI-H1304	M2n4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPDUpZKSzVyPUCuNFUzODhizszN	M2W3e3NCVkeHUh?=
NEC8	MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HWc2lEPTB;MD6wOVI5PiEQvF2=	NVfyXXNGW0GQR1XS
CAL-148	NVLXOpFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TyS2lEPTB;MD6wOVQ{QSEQvF2=	MkHTV2FPT0WU
CGTH-W-1	MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVj1RVA4UUN3ME2wMlA2PDR7IN88US=>	M3PTN3NCVkeHUh?=
NCI-H889	Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHz3XmhKSzVyPUCuNFU2QTJizszN	NH;RbFBUSU6JRWK=
GR-ST	MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwMEW2NlEh\|ryP	Mnz0V2FPT0WU
KARPAS-422	NYrpcHhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\QVJc6UUN3ME2wMlA2PjVizszN	NHnIfXFUSU6JRWK=
RPMI-8866	M2K5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\lTWM2OD1yLkC1O\|EzKM7:TR?=	MnrQV2FPT0WU
SCLC-21H	NWX4Sow2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDmRWNKSzVyPUCuNFU5QDRizszN	MmrQV2FPT0WU
COR-L88	MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjJTWM2OD1yLkC1PVI4KM7:TR?=	NIfPRWFUSU6JRWK=
LU-139	M1HWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHYTWM2OD1yLkC1PVg3KM7:TR?=	NXq0U3VRW0GQR1XS
SF126	M3TofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPMfodKSzVyPUCuNFYyOzNizszN	M3qyUHNCVkeHUh?=
NCI-H1882	M1XSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3m4Z2lEPTB;MD6wOlQzPCEQvF2=	M{nyXnNCVkeHUh?=
EW-24	NHP2ZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvWTWM2OD1yLkC2OFg{KM7:TR?=	MWXTRW5ITVJ?
CP67-MEL	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWW5ZVdEUUN3ME2wMlA3QDFizszN	MoXDV2FPT0WU
DG-75	NYX5bZZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\idmhKSzVyPUCuNFY5QTlizszN	NUK2fpN[W0GQR1XS
LOXIMVI	NX3LbYV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13qe2lEPTB;MD6wO\|AzQCEQvF2=	NG\ob45USU6JRWK=
HH	NITROoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrwO5RKSzVyPUCuNFcyPTdizszN	NGXicXZUSU6JRWK=
K5	NFTOZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjvVnY6UUN3ME2wMlA4OjJ4IN88US=>	NVjzVXFOW0GQR1XS
EC-GI-10	Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlT2TWM2OD1yLkC3NlU4KM7:TR?=	NGXJZWFUSU6JRWK=
SK-N-DZ	MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jWdmlEPTB;MD6wO\|MxPyEQvF2=	NH7hb5dUSU6JRWK=
A3-KAW	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2D1UGlEPTB;MD6wO\|M2OSEQvF2=	NEfHcYZUSU6JRWK=
MLMA	NWLmcmVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{Xk[WlEPTB;MD6wO\|Q3PSEQvF2=	MWTTRW5ITVJ?
LB996-RCC	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\odIxwUUN3ME2wMlA4PzB5IN88US=>	M1T3V3NCVkeHUh?=
OS-RC-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMEe3OFgh\|ryP	NFXVS3hUSU6JRWK=
CTB-1	M{PoZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jKR2lEPTB;MD6wO\|gyKM7:TR?=	MnfoV2FPT0WU
IST-MES1	NFvMe2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXJTWM2OD1yLkC3PVEzKM7:TR?=	NF\6SVlUSU6JRWK=
LS-1034	NHLTdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3YZ2I5UUN3ME2wMlA5ODN3IN88US=>	MkHuV2FPT0WU
HT	M1K1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TV[GlEPTB;MD6wPFA5PiEQvF2=	NV;SdINRW0GQR1XS
NCI-H2141	NHPyeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPJTWM2OD1yLkC4NUDPxE1?	M4\NVXNCVkeHUh?=
LB2518-MEL	NWCzXmVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXES3dKSzVyPUCuNFgyPDFizszN	Mo\YV2FPT0WU
GI-ME-N	NH\NSZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfve5FKSzVyPUCuNFg1PTJizszN	MUDTRW5ITVJ?
TGW	NVnwRYhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjWdpFwUUN3ME2wMlA5PjB5IN88US=>	NWrqR3czW0GQR1XS
SK-NEP-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVq5PZVmUUN3ME2wMlA5PjRzIN88US=>	NGPxfZlUSU6JRWK=
NOMO-1	NFi1WYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwMEmyO\|Uh\|ryP	NWPoeGVvW0GQR1XS
ES6	NXXPclV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFO0TIVKSzVyPUCuNFk2QDlizszN	M1ThdnNCVkeHUh?=
NCI-H209	M33PVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TyemlEPTB;MD6wPVc5PiEQvF2=	NILpcXBUSU6JRWK=
GAK	NH20U41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPCTWM2OD1yLkGwNVYh\|ryP	M2\xVXNCVkeHUh?=
BC-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMUCzOlEh\|ryP	MmToV2FPT0WU
KLE	MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo[2TWM2OD1yLkGwOFQ{KM7:TR?=	MkTtV2FPT0WU
EW-3	MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwMUC5PEDPxE1?	MmraV2FPT0WU
NKM-1	NG\XVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMUGxJO69VQ>?	NFK2V2dUSU6JRWK=
D-336MG	M2HHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLs[WhMUUN3ME2wMlEyOjR2IN88US=>	MXXTRW5ITVJ?
NB69	M3SzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nZVmlEPTB;MD6xNVMxOSEQvF2=	MVTTRW5ITVJ?
D-263MG	M2\IZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwMUG3NVIh\|ryP	MYPTRW5ITVJ?
KP-N-YS	Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jWRmlEPTB;MD6xNlI6OSEQvF2=	NYnpNXNQW0GQR1XS
NCI-H1155	NHrQb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInZVIZKSzVyPUCuNVI2PThizszN	MYnTRW5ITVJ?
BOKU	NV7UcIxPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mly3TWM2OD1yLkGyOVc6KM7:TR?=	MnnyV2FPT0WU
LAMA-84	NH;TWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnLTWM2OD1yLkGyPVkh\|ryP	M1jHeXNCVkeHUh?=
Raji	NHznVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwMUOxNVch\|ryP	MUTTRW5ITVJ?
LU-65	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nVXmlEPTB;MD6xN\|MxPyEQvF2=	MVHTRW5ITVJ?
NCI-H187	NE\GUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4mwbmlEPTB;MD6xN\|kzPCEQvF2=	MXfTRW5ITVJ?
GCIY	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTnTHIzUUN3ME2wMlE1QTBzIN88US=>	MkLrV2FPT0WU
NCI-H2107	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3VeXF3UUN3ME2wMlE2ODhizszN	NXPpOYhVW0GQR1XS
NCI-H1522	NWLqUYUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILCPWhKSzVyPUCuNVUzPjZizszN	NFXRXllUSU6JRWK=
NB6	MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DaSWlEPTB;MD6xOVYzOyEQvF2=	NGHQelRUSU6JRWK=
EM-2	MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjOTWM2OD1yLkG1O\|A3KM7:TR?=	Ml;yV2FPT0WU
HCC2218	Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPFTWM2OD1yLkG1PVgh\|ryP	NELMWmFUSU6JRWK=
NCI-H748	NVuwbG1oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NISyUpBKSzVyPUCuNVY{PzZizszN	M{K5PHNCVkeHUh?=
MS-1	NIezc45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{C4[2lEPTB;MD6xOlU{PyEQvF2=	Ml3JV2FPT0WU
NB5	NVfRNodET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjw[\|hMUUN3ME2wMlE3PTl5IN88US=>	MnvHV2FPT0WU
OMC-1	M1rFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLPUpJzUUN3ME2wMlE3Pjh6IN88US=>	NVfXcXgxW0GQR1XS
NCI-H345	NHGzeHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYD2eppzUUN3ME2wMlE3QTJ6IN88US=>	MVvTRW5ITVJ?
L-428	M{j6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jtfmlEPTB;MD6xOlk1PSEQvF2=	NX;jUnBuW0GQR1XS
SCH	NV7lfYdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnKeVVLUUN3ME2wMlE5Pjh3IN88US=>	MV7TRW5ITVJ?
NCI-H1417	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nhOmlEPTB;MD6xPVIzPyEQvF2=	NX6xcFVSW0GQR1XS
COLO-320-HSR	NGjGO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTBwMUm1N\|Ih\|ryP	NICyU2JUSU6JRWK=
BT-474	NYTRdY5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfTdGhiUUN3ME2wMlIxQDl{IN88US=>	M2XIOHNCVkeHUh?=
GDM-1	M2XNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\jTWM2OD1yLkKxPVcyKM7:TR?=	MnnlV2FPT0WU
NCI-H2196	NUTFe4FGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjyTXBKSzVyPUCuNlIzOzVizszN	MWPTRW5ITVJ?
KP-N-RT-BM-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMkKzOFkh\|ryP	MWDTRW5ITVJ?
KNS-81-FD	MlTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnSTWM2OD1yLkKyPVU5KM7:TR?=	M1TIN3NCVkeHUh?=
COLO-668	M4jYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwMkO2O\|Uh\|ryP	Mk\jV2FPT0WU
C2BBe1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vLbmlEPTB;MD6yOlc1PyEQvF2=	M{jRVXNCVkeHUh?=
Ramos-2G6-4C10	M1mw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn2yTWM2OD1yLkK2PVU1KM7:TR?=	M3\6fHNCVkeHUh?=
CAS-1	NEPtNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjuSY5KSzVyPUCuNlcxQTZizszN	M2S5ZXNCVkeHUh?=
GOTO	NYTUdFFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXzTWM2OD1yLkK3PFk1KM7:TR?=	NInaTmZUSU6JRWK=
LP-1	NIHQOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwMkiwOVch\|ryP	MYrTRW5ITVJ?
NCI-SNU-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLMTWM2OD1yLkK5OFIzKM7:TR?=	M2TueXNCVkeHUh?=
EB-3	NFW3NHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkK2TWM2OD1yLkK5PVc6KM7:TR?=	M3fafHNCVkeHUh?=
MHH-NB-11	MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwM{C0NFIh\|ryP	NVS3[JRxW0GQR1XS
SK-N-FI	NG\ofJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PUXmlEPTB;MD6zNVY6OiEQvF2=	M2PHUHNCVkeHUh?=
HCC2157	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jFd2lEPTB;MD6zN\|kyOyEQvF2=	MmfFV2FPT0WU
SIMA	Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvhb3JxUUN3ME2wMlM1PThzIN88US=>	MYLTRW5ITVJ?
MDA-MB-134-VI	NVPoUmpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3iblBZUUN3ME2wMlM3QTJ6IN88US=>	NHX4Vo9USU6JRWK=
NCI-H1694	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\ENlNJUUN3ME2wMlM4KM7:TR?=	MkLUV2FPT0WU
EHEB	NF3pU\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\scGNHUUN3ME2wMlM6ODh3IN88US=>	NV;aWYFHW0GQR1XS
U-266	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkSyTWM2OD1yLkO5PFQ3KM7:TR?=	MVfTRW5ITVJ?
LC-1F	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3LdXIzUUN3ME2wMlQ{PzZ3IN88US=>	NEW4flVUSU6JRWK=
SHP-77	Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHEVVFKSzVyPUCuOFc5PTVizszN	NUPTdJA5W0GQR1XS
LS-513	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHftRWpKSzVyPUCuOFk{ODdizszN	MXLTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. ^[4]

Protocol

Cell Research: ^[1]	+ Expand Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs Concentrations: 0.1-100 pM Incubation Time: 72 hours Method: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well. (Only for Reference)
Animal Research: ^[5]	+ Expand Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use. Dosages: 20 mg/kg Administration: Administered via i.v. (Only for Reference)

Cell Research:

^[1]

+ Expand

Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
Concentrations: 0.1-100 pM
Incubation Time: 72 hours
Method:
Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

(Only for Reference)

Animal Research:

^[5]

+ Expand

Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
Dosages: 20 mg/kg
Administration: Administered via i.v.
(Only for Reference)

References

[4] Chang J, et al. Breast Cancer Res Treat. 2012.

+ Expand

Solubility (25°C)

In vitro	DMSO	171 mg/mL (200.25 mM)
	Ethanol	18 mg/mL (21.07 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+5% Tween 80+ddH2O For best results, use promptly after mixing.	2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Paclitaxel SDF

Molecular Weight	853.91
Formula	C₄₇H₅₁NO₁₄
CAS No.	33069-62-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NSC 125973

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03400306	Not yet recruiting	Cancer - Ovarian	AbbVie	May 10 2020	Phase 1
NCT03400306	Not yet recruiting	Cancer - Ovarian	AbbVie	May 10 2020	Phase 1
NCT03417921	Not yet recruiting	Pancreatic Cancer	Ability Pharmaceuticals SL\|The Cleveland Clinic	December 1 2019	Phase 1\|Phase 2
NCT03417921	Not yet recruiting	Pancreatic Cancer	Ability Pharmaceuticals SL\|The Cleveland Clinic	December 1 2019	Phase 1\|Phase 2
NCT03818997	Not yet recruiting	Esophageal Cancer\|Biliary Tract Cancer\|GastroEsophageal Cancer\|Hepatobiliary Neoplasm	European Organisation for Research and Treatment of Cancer - EORTC\|Hoffmann-La Roche\|Leap Therapeutics Inc.	August 2019	Phase 2
NCT03818997	Not yet recruiting	Esophageal Cancer\|Biliary Tract Cancer\|GastroEsophageal Cancer\|Hepatobiliary Neoplasm	European Organisation for Research and Treatment of Cancer - EORTC\|Hoffmann-La Roche\|Leap Therapeutics Inc.	August 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?
Answer:
S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.
Question 2:
the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?
Answer:
Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

TAI-1 ^New

TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Docetaxel Trihydrate ^New

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Combretastatin A4 ^New

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with K_d of 0.4 μM.Phase 3.
Docetaxel

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Vincristine sulfate

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Nocodazole

Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole improves the CRISPR-mediated HDR efficiency and has an additive effect on enhancing precise genome editing.
Vinorelbine Tartrate

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
Cabazitaxel

Cabazitaxel is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide.

Features:A semi-synthetic derivative of a natural taxoid.
Patupilone (EPO906, Epothilone B)

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC_0.01 of 1.8 μM. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel

Cited by 22 Publications

6 Customer Reviews

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Paclitaxel SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel

Cited by 22 Publications

6 Customer Reviews

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Paclitaxel SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)